国际皮肤性病学杂志    2005 31 (3): 171-173   ISSN: 2096-5540  CN: 32-1880/R   静脉用免疫球蛋白在皮肤科临床的应用及进展 李常兴1, 张锡宝2, 吴志华1 1. 广东医学院附属医院皮肤科, 湛江 524023; 2. 广州市皮肤病防治所 收稿日期 2004-08-16  修回日期 null  网络版发布日期 null 参考文献  [1] Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med, 1999,340:227-228. [2] Hansen R J, Balthasar JP. Mechanisms of IVIG action in immune thrombocytopenic purpura. Clin Lab, 2004, 50:133 140. [3] Sultan Y, Kazatchkine MD, Maisonneuve P, et al. Anti-idiotypic suppression of autoantibodies to factor Ⅷ(antihaemophilic factor)by high-dose intravenous gammaglobulin. Lancet, 1984, 2:765. [4] May JE, Frank MM. Complement-mediated tissue damage:contribution of the classical and alternate complement pathways in the Forssman reaction. J Immunol, 1972, 108:1517-1525. [5] Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology, 1998, 51(6 Suppl 5):S2-S8. [6] Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science, 2001,291:484-486. [7] Creange A, Gregson NA, Hughes RA. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRⅡ expression in patients with chronic inflammatory neuropathies. J Neuroimmunol,2003, 135:91-95. [8] Ichiyama T, Ueno Y, Isumi H, et al. An immunoglobulin agent(IVIG)inhibits NF-kappaB activation in cultured endothelial cells of coronary arteries in vitro. Inflamm Res, 2004, 53:253-256. [9] Vassilev TL, Kazatchkine MD, Van Huyen JP, et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp(RGD)in normal immunoglobulin for therapeutic use(intravenous immunoglobulin, IVIg).Blood, 1999, 93:3624-3631. [10] Huang JL, Lee WY, Chen LC, et al. Changes of serum levels of interleukin 2, intercellular adhesion molecule 1, endothelial leukocyte adhesion molecule 1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol, 2000, 84:345-352. [11] Aktas O, Waiczies S, Grieger U, et al. Polyspecific immunoglobulins(IVIg)suppress proliferation of human(auto)antigen-specific T cells without inducing apoptosis. J Neuroimmunol, 2001, 114:160-167. [12] Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura:a randomised, multicentre trial. Lancet, 2002, 359:23-29. [13] Spahn JD, Leung DY, Chan MT, et al. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol, 1999, 103:421-426. [14] Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins:multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol, 2003,139:26-32. [15] Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol, 2002, 47:358-363. [16] Levy Y, Sherer Y, Langevitz P, et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin-a preliminary report. Clin Rheumatol, 2000,19:207-211. [17] Paul C, Lahfa M, Bachelez H, et al. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol, 2002, 147:518-522. [18] Bhatnagar SK, Paul G, Subramanian R, et al. Kawasaki disease in Oman-a clinical study. J Trop Pediatr, 2003, 49:361-366. [19] Erduran E, Aslan Y, Gedik Y, et al. A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura. Turk J Pediatr, 2003, 45:295-300. [20] O'Donnell BF, Barr RM, Black AK,et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol, 1998,138:101. [21] Mydlarski PR, Mittmann N, Shear NH. Intravenous immunoglobulin:use in dermatology. Skin Therapy Lett, 2004, 9:1 6. [22] Ruetter A, Luger TA. Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease:current view. Am J Clin Dermatol, 2004, 5:153-160. 通讯作者: